Cure My Disease

Don't miss your cure!

 Log in / Sign up

Are Europe's heart patients getting the right prevention care? a massive survey aims to find out

NCT ID NCT06495177

Knowledge-focused Sponsor: European Society of Cardiology Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 20, 2026 · Last updated Aug 21, 2026 · Updated 1 time

Summary

This observational study will enroll about 8,000 adults across Europe who have coronary heart disease or are at high risk for it, including those with diabetes or chronic kidney disease. Researchers will check whether doctors are following European guidelines for lifestyle advice and medication to prevent further heart problems. The goal is to see how well prevention targets are being met in real-world practice.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
This could reveal gaps between recommended and actual care, guiding better prevention strategies for heart disease, diabetes, and kidney disease across Europe.
What could go wrong
As an observational survey, it cannot prove cause and effect, and results may vary by country and healthcare system, limiting generalizability.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 8,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2024

Expected to finish

Dec 2029

An estimate. End dates often move.

Lead sponsor

A research network

The lead sponsor is a research network or cooperative group.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population is all consenting adult patients presenting with high risk of cardiovascular diseases identified by general practices medical note and all consenting adult patients presenting with coronary disease seen in clinic.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients having signed an informed Consent * Patients aged from 18 years old at the time of identification * At least six and at most 24 months elapsed between the index event (the recruiting diagnostic or treatment criteria below) and the date of interview * Patients meeting the recruiting diagnostic or treatment criteria: * Coronary patients: Acute coronary events (acute coronary syndrome {STEMI or NSTEMI}, unstable angina) or an emergency or elective revascularisation for coronary artery disease (CABG, PCI) * High cardiovascular disease (CVD) risk patients: patients free of CVD, who have been prescribed one or more of the following treatments: blood pressure and/or lipid-lowering and/or glucose lowering (diet and/or hypoglycaemic agents and/or insulin) Exclusion Criteria: * Patients living outside defined geographical areas * Patients admitted to hospital from outside the geographical area or under the care of cardiologists in hospitals that do not participate in EUROASPIRE VI

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute coronary syndrome are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute coronary syndrome coronary artery disorder Coronary Disease intermediate coronary syndrome Non-ST Elevated Myocardial Infarction ST-elevation myocardial infarction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute coronary syndrome Coronary disease Non-ST elevation myocardial infarction ST elevation myocardial infarction Unstable angina

Contacts and locations

Locations

  • Istanbul University, Cerrahpaşa Cardiology Institute

    Istanbul, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.